Additional file 1: of The design, fate and impact of a hospital-wide training program in evidence-based medicine for physicians – an observational study

The Critically Appraised Topic template. (DOCX 16 kb

Kaplan Meier estimate (unadjusted) of time to subsequent clinical episode (fever and any <i>P. falciparum</i>) in 1856 asymptomatic children.

<p>Kaplan Meier estimate (unadjusted) of time to subsequent clinical episode (fever and any <i>P. falciparum</i>) in 1856 asymptomatic children.</p

Parasitological findings at three cross-sectional surveys following a 6 months intervention period with different IPT regimes.

<p>These parasitological data have been presented previously <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0013649#pone.0013649-Kweku1" target="_blank">[10]</a>. The prevalence figures presented here differ slightly from those in the previous publication because it was not possible to obtain data on parasite genotype for all the children in the study due to missing samples.</p>a<p>Excluding children with clinical malaria at survey, 28 days before and 7 days after.</p>b<p>Determined by microscopy.</p>*<p>compared to the placebo group p<0.05 (Chi-square).</p

Additional file 1: of An attenuated rate of leg muscle protein depletion and leg free amino acid efflux over time is seen in ICU long-stayers

Table S1. Individual patients characteristics. Table S2. Patient characteristics at the two measurement points. Figure S1. Longitudinal presentation of plasma flow. Figure S2. Longitudinal presentation of phenylalanine turnover using the two-pool model. Figure S3. Longitudinal presentation of SOFA scores and nutrition. Figure S4. Longitudinal presentation of all amino acid fluxes. Figure S5. Amino acid concentrations. (PDF 185 kb

a) Number (n) and b) proportion (%) of PCR positive asymptomatic children infected with different number of <i>msp2</i> genotypes at the respective surveys; 1 month after the intervention, at the following dry season 6 months post-intervention, and at the end of the following rainy season 12 months post-intervention.

<p>The number within brackets in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0013649#pone-0013649-g002" target="_blank">Figure 2a</a> represents the total number of children in the respective groups.</p

Study outline.

<p>Intermittent preventive treatment or placebo was given over a six month-period spanning peak malaria transmission season, followed by a 12- month post intervention surveillance period. Cross-sectional surveys were performed 1 month (November 2005), 6 months (April 2006) and 12 months (November 2006) after the intervention was stopped. Blood films and filter paper samples were collected at these three time points.</p

Risk for subsequent clinical malaria in asymptomatic children (n = 1856) during the 12 months follow up after the intervention.

<p>The AS+AQ monthly group is not included in the table since no parasite positive children developed a clinical episode during follow up.</p>*<p>reference group.</p>a<p>adjusted for age.</p>b<p>adjusted for age and treatment group.</p><p>NA not applicable.</p><p>No significant deviations from the proportional hazards assumptions were found.</p

Kaplan Meier estimate (unadjusted) of time to subsequent clinical episode (fever and any <i>P. falciparum</i>) in 1856 asymptomatic children; a) placebo, b) SP bimonthly c) AS+AQ bimonthly and d) AS+AQ monthly.

<p>In the AS+AQ monthly group no children with parasites at the survey after ended intervention developed clinical malaria.</p

Syndromes overlap and mortality among the 61 cohort children admitted with severe malaria to Kilifi District Hospital.

<p>Four children died (marked *).</p

Assessment of exposure in three-monthly visits from birth until admission^a in 61 children admitted with severe malaria.

<p>a. samples until 2 years of age at most.</p><p>b. cases with impaired consciousness with or without other syndromes.</p><p>c. including respiratory distress and severe malaria anemia and not impaired consciousness.</p><p>d. ever detected in all samples.</p><p>e. total number of clones detected in an individual including all visits.</p><p>f. exposed (parasite positive and/or antibodies to schizont extract at least once) n (%).</p><p>g. not exposed as determined by PCR and antibodies to schizont extract.</p